EOLS Q3 2021 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena

EOLSEvolus, Inc.

$338M

Q3 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$27M+51.1% YoY

Gross Profit

$15M56.9% margin

Operating Income

-$19M-71.6% margin

Net Income

-$19M-72.8% margin

EPS (Diluted)

$-0.35

QoQ Revenue Growth

+2.2%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$32M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$215M

Total Liabilities

$118M

Stockholders' Equity

$97M

Cash & Equivalents

$108M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$27M	$18M	+51.1%
Gross Profit	$15M	$11M	+37.3%
Operating Income	-$19M	-$11M	-70.2%
Net Income	-$19M	-$11M	-69.6%

Revenue Segments

Product

$27M100%